Abbvie (ABBV) PT Raised to $128 at Mizuho Securities
Tweet
Share
E-mailGet Alerts ABBV Hot Sheet
Price: $234.87 +2.11%
Rating Summary:
26 Buy, 12 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 6 | Down: 13 | New: 23
Rating Summary:
26 Buy, 12 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 6 | Down: 13 | New: 23
Join SI Premium – FREE
Mizuho Securities analyst Vamil Divan raised the price target on Abbvie (NYSE: ABBV) to $128.00 (from $126.00) while maintaining a Buy rating.
You May Also Be Interested In
- Abbvie (ABBV) PT Raised to $273 at Canaccord
- AbbVie Announces European Commission Approval of SKYRIZI® (risankizumab) for the Treatment of Pediatric Patients with Moderate to Severe Plaque Psoriasis
- AbbVie Announces European Commission Approval of MAVIRET® (Glecaprevir/Pibrentasvir) for People with Acute Hepatitis C Virus Infection
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
